Open AccessTurkish IBD Organization’s Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic
Author(s) -
Murat Törüner,
İsmail Hakkı Kalkan,
Filiz Akyüz,
Ahmet Tezel,
Aykut Ferhat Çelık
Publication year - 2021
Publication title -
pubmed central
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
DOI - 10.5152/tjg.2021.280721
Subject(s) - medicine , pandemic , inflammatory bowel disease , context (archaeology) , covid-19 , intensive care medicine , disease , immunology , virology , infectious disease (medical specialty) , outbreak , biology , paleontology
The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic.